Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate.
Function
LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bonemetabolism, cachexia, neural development, embryogenesis and inflammation. p53 regulated LIF has been shown to facilitate implantation in the mouse model and possibly in humans.[5] It has been suggested that recombinant human LIF might help to improve the implantation rate in women with unexplained infertility.[6]
LIF is normally expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. As embryonic stem cells are derived from the inner cell mass at the blastocyst stage, removing them from the inner cell mass also removes their source of LIF. Recombinant LIF has been produced in plants by InVitria.
Use in stem cell culture
LIF is often added to stem cell culture media as an alternative to feeder cell culture, due to the limitation that feeder cells present by only producing LIF on their cell surfaces. Feeder cells lacking the LIF gene do not effectively support stem cells.[7] LIF promotes self-renewal by recruiting signal transducer and activator of transcription 3 (Stat3). Stat3 is recruited to the activated LIF receptor and phosphorylated by Janus kinase. It bears noting that LIF and Stat3 are not sufficient to inhibit stem cell differentiation, as cells will differentiate upon removal of serum. During the reversibility phase of differentiation from naive pluripotency, it is possible to revert cells back to naive pluripotency through the addition of LIF.[8]
Removal of LIF pushes stem cells toward differentiation, however genetic manipulation of embryonic stem cells allows for LIF independent growth, notably overexpression of the gene Nanog.
LIF is typically added to stem cell culture medium to reduce spontaneous differentiation.[9][10]
Králícková M, Síma P, Rokyta Z (2005). "Role of the leukemia-inhibitory factor gene mutations in infertile women: the embryo-endometrial cytokine cross talk during implantation--a delicate homeostatic equilibrium". Folia Microbiologica. 50 (3): 179–86. doi:10.1007/BF02931563. PMID16295654. S2CID22515632.
Lowe DG, Nunes W, Bombara M, McCabe S, Ranges GE, Henzel W, Tomida M, Yamamoto-Yamaguchi Y, Hozumi M, Goeddel DV (June 1989). "Genomic cloning and heterologous expression of human differentiation-stimulating factor". DNA. 8 (5): 351–9. doi:10.1089/dna.1.1989.8.351. PMID2475312.
Sutherland GR, Baker E, Hyland VJ, Callen DF, Stahl J, Gough NM (January 1989). "The gene for human leukemia inhibitory factor (LIF) maps to 22q12". Leukemia. 3 (1): 9–13. PMID2491897.
Mori M, Yamaguchi K, Abe K (May 1989). "Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia". Biochemical and Biophysical Research Communications. 160 (3): 1085–92. doi:10.1016/S0006-291X(89)80114-7. PMID2730639.
Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA, Gough NM (December 1988). "Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells". Nature. 336 (6200): 684–7. Bibcode:1988Natur.336..684W. doi:10.1038/336684a0. PMID3143916. S2CID4346252.
Moreau JF, Donaldson DD, Bennett F, Witek-Giannotti J, Clark SC, Wong GG (December 1988). "Leukaemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cells". Nature. 336 (6200): 690–2. Bibcode:1988Natur.336..690M. doi:10.1038/336690a0. PMID3143918. S2CID4259150.
Yamaguchi M, Miki N, Ono M, Ohtsuka C, Demura H, Kurachi H, Inoue M, Endo H, Taga T, Kishimoto T (March 1995). "Inhibition of growth hormone-releasing factor production in mouse placenta by cytokines using gp130 as a signal transducer". Endocrinology. 136 (3): 1072–8. doi:10.1210/endo.136.3.7867561. PMID7867561.
Schmelzer CH, Harris RJ, Butler D, Yedinak CM, Wagner KL, Burton LE (May 1993). "Glycosylation pattern and disulfide assignments of recombinant human differentiation-stimulating factor". Archives of Biochemistry and Biophysics. 302 (2): 484–9. doi:10.1006/abbi.1993.1243. PMID8489250.
Aikawa J, Ikeda-Naiki S, Ohgane J, Min KS, Imamura T, Sasai K, Shiota K, Ogawa T (September 1997). "Molecular cloning of rat leukemia inhibitory factor receptor alpha-chain gene and its expression during pregnancy". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1353 (3): 266–76. doi:10.1016/s0167-4781(97)00079-1. PMID9349722.
Tanaka M, Hara T, Copeland NG, Gilbert DJ, Jenkins NA, Miyajima A (February 1999). "Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit". Blood. 93 (3): 804–15. doi:10.1182/blood.V93.3.804. PMID9920829. S2CID39078004.
Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, Miyazono K, Taga T (April 1999). "Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300". Science. 284 (5413): 479–82. Bibcode:1999Sci...284..479N. doi:10.1126/science.284.5413.479. PMID10205054.
Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP (December 1999). "The DNA sequence of human chromosome 22". Nature. 402 (6761): 489–95. Bibcode:1999Natur.402..489D. doi:10.1038/990031. PMID10591208.
